TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial Regarding the Acceptability of an Audiotape Questionnaire for Intimate Partner Violence Screening in a Pediatric ED
Brief Summary: The purpose of this study is to compare the safety, acceptability and ease of the administration of two screening methods, a pen and paper questionnaire and an audiotape with headsets, for screening for intimate partner violence in a pediatric emergency department (ED).


Options:
A: Arm Label: Model Care (SEEK); Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced pediatric primary care | Arm Label: Standard pediatric primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard pediatric primary care | Intervention Type: BEHAVIORAL; Name: Enhanced pediatric primary care; Assigned to Arm(s): Model Care (SEEK) | Intervention Type: BEHAVIORAL; Name: Standard pediatric primary care; Assigned to Arm(s): Standard pediatric primary care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2
C: Intervention Type: PROCEDURE; Name: Woman Abuse Screening Tool; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Partner Violence Screen; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Computerized screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Face to face screening; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Written screening on forms; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Screening via pen and paper; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Screening via audiotape; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Brief Summary: The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer. Overall survival will be taken as the primary measure of efficacy.


Options:
A: Arm Label: Cetuximab Plus Chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU) | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Platinum (Cisplatin or Carboplatin) + 5-FU | Intervention Type: DRUG; Name: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU); Assigned to Arm(s): Cetuximab Plus Chemotherapy | Intervention Type: DRUG; Name: Platinum (Cisplatin or Carboplatin) + 5-FU; Assigned to Arm(s): Chemotherapy alone
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Radiation: intensity-modulated radiation therapy (IMRT), Drug: Paclitaxel, Drug: Cisplatin | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy (IMRT); Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Group 1, Group 2
C: Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Radiotherapy 70 Gy, 35 fractions; Assigned to Arm(s): N/A
D: Arm Label: Standard fractionation RT + cisplatin; Type: OTHER; Interventions: Drug: cisplatin, Radiation: Standard fractionation RT, Procedure: Conventional surgery for select patients | Arm Label: Accelerated fractionation RT + cisplatin; Type: EXPERIMENTAL; Interventions: Drug: cisplatin, Radiation: Accelerated fractionation radiation therapy, Procedure: Conventional surgery for select patients | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Standard fractionation RT; Assigned to Arm(s): Standard fractionation RT + cisplatin | Intervention Type: RADIATION; Name: Accelerated fractionation radiation therapy; Assigned to Arm(s): Accelerated fractionation RT + cisplatin | Intervention Type: PROCEDURE; Name: Conventional surgery for select patients; Assigned to Arm(s): Accelerated fractionation RT + cisplatin, Standard fractionation RT + cisplatin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration
Brief Summary: Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled, intervention trial was conducted in a general population of South Africa to test this hypothesis.


Options:
A: Arm Label: Circumcised immediately; Type: ACTIVE_COMPARATOR; Interventions: Procedure: male circumcision | Arm Label: Delayed Circumcision; Type: PLACEBO_COMPARATOR; Interventions: Procedure: male circumcision | Intervention Type: PROCEDURE; Name: male circumcision; Assigned to Arm(s): Circumcised immediately, Delayed Circumcision
B: Intervention Type: PROCEDURE; Name: Male Circumcision; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Adult male circumcision; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Stepping Stones | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: stepping Stones short | Intervention Type: BEHAVIORAL; Name: Stepping Stones; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: stepping Stones short; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Safe Male Circumcision on Incidence of Infection by HIV, HSV-2 and of Genital Ulceration
Brief Summary: Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled, intervention trial was conducted in a general population of South Africa to test this hypothesis.


Options:
A: Intervention Type: PROCEDURE; Name: Male Circumcision; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Shang Ring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Male circumcision | Intervention Type: DEVICE; Name: Shang Ring; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Male circumcision; Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: PrePex device for male circumcision; Assigned to Arm(s): N/A
D: Arm Label: PrePex™; Type: EXPERIMENTAL; Interventions: Device: PrePex™ device for adult male circumcision | Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical circumcision | Intervention Type: DEVICE; Name: PrePex™ device for adult male circumcision; Assigned to Arm(s): PrePex™ | Intervention Type: PROCEDURE; Name: Surgical circumcision; Assigned to Arm(s): Surgical

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.
Brief Summary: Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the efficacy of GSK Biologicals HPV 16/18 VLP/AS04 vaccine to prevent infection associated cervical pre-cancer and vaccine with HPV 16 or 18 and the vaccine safety, over 48 months, in young adolescents and women of 15/25 years of age at study start. Approximately 18.000 study subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Cervarix Group; Type: OTHER; Interventions: Procedure: Blood sampling | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
C: Arm Label: Cervarix (15-25 Years) Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Cervarix (26-45 Years) Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Arm Label: Cervarix (46-55 Years) Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix (15-25 Years) Group, Cervarix (26-45 Years) Group, Cervarix (46-55 Years) Group
D: Arm Label: qHPV Vaccine; Type: EXPERIMENTAL; Interventions: Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: placebo (unspecified) | Intervention Type: BIOLOGICAL; Name: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Assigned to Arm(s): qHPV Vaccine | Intervention Type: BIOLOGICAL; Name: Comparator: placebo (unspecified); Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Double-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy of GlaxoSmithKline Biologicals. HPV-16/18 VLP AS04 Vaccine Compared to Hepatitis A Vaccine as Control in Prevention of Persistent HPV-16 or HPV-18 Cervical Infection and Cervical Neoplasia, Administered Intramuscularly According to a 0, 1, 6 Month Schedule in Healthy Females 15-25 Years of Age.
Brief Summary: Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the efficacy of GSK Biologicals HPV 16/18 VLP/AS04 vaccine to prevent infection associated cervical pre-cancer and vaccine with HPV 16 or 18 and the vaccine safety, over 48 months, in young adolescents and women of 15/25 years of age at study start. Approximately 18.000 study subjects will either receive the HPV vaccine or a control vaccine (hepatitis A vaccine) administered intramuscularly according to a 0-1-6 month schedule.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Celecoxib | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): A
B: Arm Label: Arm I (celecoxib); Type: EXPERIMENTAL; Interventions: Drug: celecoxib | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): Arm I (celecoxib) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II (placebo)
C: Arm Label: Arm I (celecoxib); Type: EXPERIMENTAL; Interventions: Drug: Celecoxib, Other: Laboratory Biomarker Analysis | Arm Label: Arm II (placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Other: Placebo | Intervention Type: DRUG; Name: Celecoxib; Assigned to Arm(s): Arm I (celecoxib) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (celecoxib), Arm II (placebo) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II (placebo)
D: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Hypertension in the Very Elderly Trial (HYVET)
Brief Summary: The purpose of this study is to assess the benefits and risks of treating very elderly (those aged 80 or older) individuals with hypertension.


Options:
A: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Naproxen Sodium (Aleve); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Celecoxib (Celebrex); Assigned to Arm(s): N/A
C: Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging
D: Arm Label: Standard health counseling at baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Nutritional guidance, Behavioral: Exercise, Behavioral: Cognitive training, Other: Reduction of vascular risk factors | Intervention Type: BEHAVIORAL; Name: Nutritional guidance; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Cognitive training; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: Reduction of vascular risk factors; Assigned to Arm(s): Lifestyle counseling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Hypertension in the Very Elderly Trial (HYVET)
Brief Summary: The purpose of this study is to assess the benefits and risks of treating very elderly (those aged 80 or older) individuals with hypertension.


Options:
A: Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo
B: Arm Label: Olmesartan medoxomil; Type: ACTIVE_COMPARATOR; Interventions: Drug: olmesartan medoxomil | Arm Label: Standard therapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): Olmesartan medoxomil
C: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Hypertension in the Very Elderly Trial (HYVET)
Brief Summary: The purpose of this study is to assess the benefits and risks of treating very elderly (those aged 80 or older) individuals with hypertension.


Options:
A: Arm Label: A,1,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Arm Label: A,2,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Arm Label: A,3,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Arm Label: A,4,IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin | Intervention Type: DRUG; Name: Amlodipine, Telmisartan, Amiloride Compound , Simvastatin; Assigned to Arm(s): A,1,IV, A,2,IV, A,3,IV, A,4,IV
B: Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
D: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Hypertension in the Very Elderly Trial (HYVET)
Brief Summary: The purpose of this study is to assess the benefits and risks of treating very elderly (those aged 80 or older) individuals with hypertension.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin
C: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
D: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Hypertension in the Very Elderly Trial (HYVET)
Brief Summary: The purpose of this study is to assess the benefits and risks of treating very elderly (those aged 80 or older) individuals with hypertension.


Options:
A: Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Indapamide SR 1.5mg; Perindopril 2-4mg; Assigned to Arm(s): N/A
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: chlortalidone-amiloride; Type: EXPERIMENTAL; Interventions: Drug: Chlorthalidone plus amiloride | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): chlortalidone-amiloride | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control

Answer: B